Trial Profile
A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Olanzapine (Primary) ; Olanzapine (Primary) ; Haloperidol decanoate; Haloperidol decanoate
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms HGMT
- Sponsors Eli Lilly and Company
- 30 Jul 2022 This trial has been completed in France (End Date: 13 June 2008) according to European Clinical Trials Database record.
- 18 Aug 2011 This trial is recruiting in France and has discontinued in Hungary and United Kingdom.
- 18 Aug 2011 New trial record